Efficiency and effectiveness evaluation of an automated multi-country patient count cohort system by Soto Rey, I. (Iñaki) et al.
Soto-Rey et al. BMC Medical Research Methodology  (2015) 15:44 
DOI 10.1186/s12874-015-0035-9RESEARCH ARTICLE Open AccessEfficiency and effectiveness evaluation of an
automated multi-country patient count cohort
system
Iñaki Soto-Rey1*, Benjamin Trinczek1, Yannick Girardeau2,3, Eric Zapletal2, Nadir Ammour4, Justin Doods1,
Martin Dugas1 and Fleur Fritz1Abstract
Background: With the increase of clinical trial costs during the last decades, the design of feasibility studies has
become an essential process to reduce avoidable and costly protocol amendments. This design includes timelines,
targeted sites and budget, together with a list of eligibility criteria that potential participants need to match.
The present work was designed to assess the value of obtaining potential study participant counts using an
automated patient count cohort system for large multi-country and multi-site trials: the Electronic Health Records
for Clinical Research (EHR4CR) system.
Methods: The evaluation focuses on the accuracy of the patient counts and the time invested to obtain these
using the EHR4CR platform compared to the current questionnaire based process. This evaluation will assess the
patient counts from ten clinical trials at two different sites. In order to assess the accuracy of the results, the
numbers obtained following the two processes need to be compared to a baseline number, the “alloyed” gold
standard, which was produced by a manual check of patient records.
Results: The patient counts obtained using the EHR4CR system were in three evaluated trials more accurate than
the ones obtained following the current process whereas in six other trials the current process counts were more
accurate. In two of the trials both of the processes had counts within the gold standard’s confidence interval.
In terms of efficiency the EHR4CR protocol feasibility system proved to save approximately seven calendar days in
the process of obtaining patient counts compared to the current manual process.
Conclusions: At the current stage, electronic health record data sources need to be enhanced with better
structured data so that these can be re-used for research purposes. With this kind of data, systems such as the
EHR4CR are able to provide accurate objective patient counts in a more efficient way than the current methods.
Additional research using both structured and unstructured data search technology is needed to assess the value
of unstructured data and to compare the amount of efforts needed for data preparation.
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Scientific background
Clinical Trials (CTs) are essential for the improvement
and development of preventive and therapeutic strat-
egies, epidemiology and healthcare. The complexity and
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unless otherwise stated.decades [1]. Oftentimes they are delayed or even can-
celled, which results in a tremendous loss for the institu-
tions that fund them [2].
As a strategy to avoid such loss, it has been established
that every CT starts with a feasibility study, defined by
Arain as a “piece of research done before a main study,
[…] used to estimate important parameters that are
needed to design the main study” [3]. These parameters
are, besides others, timelines, targets and costs of per-
forming a CT in determined geographical regions. Toal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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conduction of CTs, feasibility studies also include a list
of eligibility criteria (EC) that potential study partici-
pants need to match. The study design process starts
with a series of meetings, through which the feasibility
study team decides the main objectives of the study and
produces an initial study draft, called protocol synopsis.
Secondly, one or several country feasibility managers
evaluate the feasibility of the trial in certain countries.
This process requires basic feasibility data such as
patient counts that would match the trial’s EC. Those
counts are usually obtained by consulting clinicians at
different sites within the countries - a costly and ineffi-
cient process [4]. In the next step of the protocol design,
site feasibility managers ask potential study sites about
their commitment regarding the number of patients they
can enrol and other relevant information for the trial
such as technological and human resources. Based on all
this information, the feasibility study team decides on
the final list of sites and the study protocol, which both
get documented in the final study design [5].
Modifications of the study protocol lead to the repeti-
tion of: cohort definition by criteria, approaching the
country feasibility managers and sites, estimations col-
lection and finally comparison of these estimations to a
recruitment goal and necessary cohort size respectively.
All these repetitions result in cumbersome, slow and
costly work.
There is general consensus that a well-defined study
protocol leads to fewer protocol amendments, and thus
a decrease in the final trial cost [6]. Eventually, better,
faster and less costly feasibility studies lead to a better
success rate of clinical trials [7]. Several experts agree on
the need for improvement of the protocol feasibility
phase, and even categorize it as one with the greatest
potential for improvement [8].
There is a growing awareness of the importance of
electronic health records (EHRs) for the improvement of
healthcare [9] and clinical research [10].
With the purpose of reusing EHR data from different
countries to support clinical trials [11], the Innovative
Medicine Initiative (IMI) [12] launched one of its biggest
initiatives in 2010: the Electronic Health Records for
Clinical Research (EHR4CR) project [13], in which this
research was focused.
Rationale for the study
The EHR4CR project includes four scenarios that cover
the clinical trial steps of: (1) clinical protocol feasibility
(PF), (2) patient identification and recruitment, (3) clin-
ical trial execution and (4) adverse event reporting. The
main objectives of the first phase of the project are to
support the design of study protocols and to improve
the country feasibility step of PF. The EHR4CR PFsystem supports these processes by providing patient
counts for certain user-selected EC from several sites
across different countries. Thus, clinicians do not need
to be approached when seeking for eligible patient
counts and objective results can be obtained.
Several internal tests proved the reliability of the
platform and the effectiveness of the algorithm that cal-
culates the eligible patients within the EHR4CR local
data-warehouses, but all these experiments were based
on test data and an evaluation of the platform perform-
ance in a real scenario was still needed.
Objectives of the study
To test the reliability of the EHR4CR PF system in a
real-case scenario, the objective of this work is to evalu-
ate the effectiveness, defined by the International
Organization for Standardization as: accuracy and com-
pleteness with which users achieve specified goals; and
the efficiency: resources expended in relation to the
accuracy and completeness with which users achieve
goals [14]; in the processes of obtaining patient counts
that match certain EC. A comparison was made between
the current manual processes to obtain these counts and
the counts obtained using an automated patient count
cohort system such as the EHR4CR PF system.
This research was approved by the internal EHR4CR
scientific committee, the Münster ethics committee and
the data protection managers and clinic directors of the
sites involved in the evaluation.
Study context
Two EHR4CR sites participated in this evaluation:
the Assistance Publique-Hôpitaux de Paris in France
(AP-HP) and the University Hospital Münster in
Germany (UKM), involving two clinics from the AP-HP
(Departments of Urology and Pneumology) and 7 from the
UKM (Departments of Medicine A, B, C, D, Urology,
Neurology and Gynaecology).
System details and systems in use: The EHR4CR system
The EHR4CR PF technical platform is based on a com-
plex architecture [15], with an algorithm that transforms
graphically user-created sets of rules into machine read-
able language. A web based information system has been
developed to facilitate the creation and management of
protocol feasibility studies, each of them containing one
or several protocol feasibility queries. This EHR4CR PF
system contains a so called “query builder”, which uses
specific EHR4CR terminology services [16] for the selec-
tion of EC. The query builder also contains as well tem-
poral constrains (e.g. X before/after Y) and all the
necessary Boolean logic to build PF queries. These global
queries are sent though certified secured web-channels
to the user selected endpoints located at the hospital
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and the patient counts matching the EC are sent back to
the EHR4CR PF system where they can be visualized.
The EHR4CR PF system ensures the anonymity of the
data displaying only patient counts higher than five and
fuzzing the counts when the result is lower than five.
Several of the EHR4CR data providers also shifted the
dates of the data elements within their EHR4CR data
warehouses between zero and 365 days.
Selection of studies
At the beginning of the year 2011, all ten European
Federation of Pharmaceutical Industries and Associations
(EFPIA) companies participating in the project were asked
to deliver a list of recently completed (within the last two
years) or ongoing studies (with completed feasibility phase)
running at the participating sites.
From the initial list of 267 trials, ten studies were
selected based on criteria so that a) each EFPIA com-
pany and b) each data provider site participating in the
EHR4CR project were represented at least once. Studies
running at several sites were prioritized from those run-
ning at a fewer sites.
Feasibility experts from the collaborating EFPIA part-
ners simplified the free text EC of these studies and
extracted ‘non-ambiguous data elements’. Since this
work was focused on PF, criteria that were not essential
for feasibility were removed (e.g. in the case of theTable 1 List of selected studies
Title EFPIA pa
Once – Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The
Long-Term Prevention Of Recurrent Symptomatic Venous
Thromboembolism In Patients With Symptomatic Deep-Vein
Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study
Bayer
E.V.O.L.V.E. Trial™: Evaluation Of Cinacalcet HCl Therapy to Lower
CardioVascular Events
Amgen
Safinamide in Idiopathic Parkinson’s Disease (IPD) With Motor
Fluctuations, as add-on to Levodopa (SETTLE)
Merck
Six Months Efficacy and Safety of Aliskiren Therapy on Top of
Standard Therapy, on Morbidity and Mortality in Patients With
Acute Decompensated Heart Failure
Novartis
Abiraterone Acetate in Castration-Resistant Prostate Cancer
Previously Treated With Docetaxel-Based Chemotherapy
Janssen
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist)
in Non-metastatic Hormone Resistant Prostate Cancer (ENTHUSE M0)
Astra-Zen
GLP-1 Agonist AVE0010 in Patients With Type 2 Diabetes for
Glycemic Control and Safety Evaluation, on Top of Basal Insulin
Sanofi
A Study of Taspoglutide in Patients With Inadequately Controlled
Diabetes Mellitus Type 2 and Cardiovascular Disease
Roche
A Study in Participants With Type 2 Diabetes Mellitus Lilly
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment
Optimisation) Study; BIG 2-06/N063D
GSK
Details of the selected studies (name, company, disease areas) together with the orNCT01018173 trial, 26 criteria were extracted after the
simplification, but for feasibility only 5 were relevant).
Table 1 summarizes the ten studies and shows how
many criteria were selected as feasibility EC.
The EC data elements were then used to identify the
corresponding data in the EHRs and mappings from
local to central terminology codes were created. The
clinical data warehouses (CDWs) at each site were filled
with the mapped EHR data; so that queries generated
using the EHR4CR PF system could retrieve valid patient
counts from the sites. This process is also known as the
Extraction, Transformation and Load of data (ETL).
Methods
The evaluation process of the EHR4CR PF scenario
started in May 2013 with the target decision of the
evaluation. The studies used for the evaluation were the
same ten trials used for building the PF scenario and the
data utilized were from 2012.
Effectiveness
The first objective of this evaluation was to evaluate the
accuracy of the patient counts provided by the EHR4CR
system and the current manual process. This was
achieved by comparing these two values to a gold stand-
ard (defined below).The accuracy of the two processes
was assessed by analysing whether the EHR4CR system
produces closer counts to the gold standard than thertner Disease category Original number
of EC
Number of
feasibility criteria
Cardiovascular- PE/DVT 6 6
Cardiovascular 3 3
Nervous system
disorders- Parkinson
19 5
Cardiovascular 22 16
Oncology 11 11
eca Oncology 30 3
Diabetes 20 20
Cardiovascular + Diabetes 25 3
Diabetes 16 16
Oncology 26 26
iginal number of EC vs the reduced number of feasibility EC.
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Therefore, three different values needed to be obtained
for the effectiveness evaluation: the patient counts obtained
following the current manual process, the ones obtained
using the EHR4CR PF system and those belonging to
the gold standard.
Simulation of the current manual process
For each of the selected studies, a questionnaire was sent
to a clinician of the participating sites in order to collect
their estimation of the number of patients that would be
eligible to participate in the respective study per year at
their clinic or department. EFPIA members involved in
the evaluation made necessary arrangements with the
sites to introduce the subject and seek their participa-
tion. The questionnaire contained the estimation of
matching patients and two additional questions about
the common PF process and current PF issues that were
used for the interpretation of the results in the discus-
sion. The procedure to answer the questionnaire should
be the same as the one the clinicians normally follow in
order to answer to clinical trial feasibility questionnaires.
An example of the questionnaire can be found in the
supplement [see Additional file 1].
If the evaluated site was not part of the original study,
the site itself was responsible for obtaining the estima-
tions. The method followed was to contact the clinic di-
rectors and forward them the questionnaire so they
could find the right person to answer it and return the
results.
New process: the EHR4CR PF system
The study population used for the evaluation consisted
of all patients who visited the evaluated clinics during
the year 2012. Seven different EHR4CR databases were
created at UKM and two at AP-HP corresponding to the
number of clinics evaluated at each site.
A medical expert with basic knowledge of the EHR4CR
PF system created the studies using the EHR4CR query
builder. The queries were then executed and the results
stored. The complete set of queries can be found in the
supplement [see Additional file 2].
The temporal constraints of the EHR4CR queries were
adapted according to the date shift of the EHR4CR data
elements: As the date of the elements is shifted in some
of the sites between zero and 365 days, two criteria
related to each other with both a temporal constraint
shorter than 365 days could be biased.
Chart Review - “Alloyed” gold standard
Gold standard [17] was defined as the result from a
manual check of patient records. Due to the impractic-
ability to review several thousands of patient records, an
alloyed gold standard [18] was used instead, recurring toWilson Score Confidence Interval for Binomial Propor-
tion (CI =WILSON) [19] to build it.
The two-sided 100(1-α)% confidence interval for ρ is:
X þ
z2
1−α2
2
N þ z21−α2
 z1−
α
2
N
1
2
N þ z21−α2
ρ^ 1−ρ^ð Þ þ
z21−α2
4N
 !1
2
So the half-width for the two-sided 100(1-α)% confi-
dence interval is:
half width ¼ z1−α=2N
1
2
N þ z21−α=2
ρ^ 1−ρ^ð Þ þ
z21−α=2
4N
 !1
2
Prob(Width) is calculated exactly by adding up the
probabilities of observing each X ϵ {1……N} that pro-
duces a confidence interval whose half-width is at most
a target value h:
Prob Widthð Þ ¼
XN
i¼0
P X ¼ ið Þlhalf width < h
According to this formula, checking at least 93 pa-
tients would be sufficient to then extrapolate and obtain
a 95% of confidence. In some cases, more than one of
the trials covered the same disease category, and we
therefore used the same set of patient records for those
studies. For example, if trial A and trial B are diabetes
mellitus type II studies, the same set of patient records
can be used to assess the eligibility of each patient for
the two trials. The patient records were manually
reviewed by medically qualified personnel from the eval-
uated sites.
After the initial review, the results were checked a sec-
ond time and conflicting cases were discussed with the
responsible clinicians, who decided the eligibility of the
patient. Once all the results were obtained, the number
of eligible patients from the seven (at UKM) and two
(at AP-HP) manually checked 100-patients sets were
extrapolated.
Efficiency
The second objective of the evaluation was to estimate
the time required in obtaining patient counts that match
certain EC first following the current manual process
and second using the EHR4CR PF system. Evaluating
the efficiency of these processes does not require an
“alloyed” gold standard in this context as the gold stand-
ard would be the faster process. In the first case, the
value is obtained by measuring the time involved in
preparing the questionnaire, sending it and obtaining
the results. For the EHR4CR PF process, the time value
is obtained by measuring the time invested in logging
into the EHR4CR platform, creating the queries and
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obtained using the stopwatch method.
100 patient records test
The first results from the UKM site showed an unex-
pected high number of mismatches between the
“alloyed” gold standard and the EHR4CR PF system.
With the purpose of discovering the reason for this mis-
match, an additional in-depth analysis of the cohorts
was conducted at UKM. To retrieve the necessary infor-
mation, a dedicated EHR4CR database with the 100 pa-
tient records manually checked for the NCT01018173
Roche trial was created. Each entry in the database was
analysed separately to find the reasons for the differ-
ences between the PF system’s calculated numbers and
the “alloyed” gold standard.
Results
Effectiveness
The first values required for the evaluation were the
patient counts obtained by simulating the current
process: the responses given from clinicians to the
protocol feasibility questionnaire. A total number of nine
clinicians (two at AP-HP and seven at UKM) were con-
tacted: three of them (two at AP-HP, and one at UKM)
by the corresponding EFPIA companies and the other
six directly by the sites. All clinicians responded with es-
timated patient counts and feedback about the current
PF process and issues. The estimations cover a range
from ten to 340 potentially matching patients per year
and clinic, based on the correspondent EC. The free text
feedback from the clinicians can be found in the supple-
ment [see Additional file 3]. Two of the clinicians stated
that they contrast their opinion with health records in
order to answer to feasibility questionnaires. Other
three, that they base their responses on their own ex-
perience. The rest of the clinicians either did not answerTable 2 Results of the query execution using the EHR4CR PF
Study EFPIA partner C1 C2 C3 C4 C5 C6 C7
NCT00439725 Bayer 1411 30 0
NCT00345839 Amgen 0 15 23 −7*
NCT00627640 Merck 4331 128 28 <5 -<5*
NCT00894387 Novartis 1884 412 0 884 0* 0* −341
NCT00638690 Janssen 1437 174 64 0 64 0*
NCT00626548 AstraZeneca 1158 1437 174
NCT00715624 Sanofi 573 18 −400* −57* 0*
NCT01018173 Roche 2570 573 44
NCT01468987 Eli Lilly 573 775 0* −8* −53* 0* −106
Columns C1 to C11 show the number of eligible patients for every single criterion,
patients who visited the respective clinics in the year 2012.
Results for the GSK- NCT00490139 trial are excluded due to formatting issues and c
*Exclusion criterion.to the question or the response was too ambiguous to
consider it. The complete set of responses will be used
for interpretation in the discussion.
The second value required was the result of the feasi-
bility process using the EHR4CR PF system. All executed
queries yielded in calculated patient counts, with results
from zero to 695 matching patients. Table 2 lists the cal-
culated patient counts for the queries executed at UKM.
As it can be seen in Table 3, the results for AP-HP con-
tain a higher number of patients matching the study
criteria.
The results of the chart review for the evaluated studies
at the two sites can be visualized in the Tables 4 and 5. Eli-
gible patients were found in a range between zero and 34
patients out of the 100-patient records sets. These num-
bers were extrapolated using the ci-Wilson score resulting
in a range between zero and 1035 eligible patients between
the lowest and the highest means. The lower ci-Wilson
bounds vary between zero and 655 patients and the upper
bounds between 54 and 1709 patients.
The comparison between the three values: estimations
from clinicians, results from the EHR4CR PF system and
chart reviews (Tables 6 and 7), shows that the values
from EHR4CR PF system were within the bounds of the
confidence interval in three cases. In one of those three
cases the estimation from the clinician was below the
lower bound, in the other two cases the clinician estima-
tions were as well within the confidence interval. In ten
other cases, the EHR4CR PF system values were below
the lower bound. In six out of these ten cases, the clin-
ician estimations were within the confidence interval.
Out of the four cases in which both values were under
the lower bound of the “alloyed” gold standard, in two of
them the response from the EHR4CR system was closer
to the “alloyed” gold standard and in the other two the
estimations from the clinicians were the closer ones. As
a summary, the counts provided by the EHR4CR PFsystem at UKM
C8 C9 C10 C11 Eligible patients Patients per clinic
0 1411
0 7439
0 5606
* 0* 0* −163* 0* 0 1887
0 1540
174 1540
18 2575
566 2575
* −89* −301* 11 8 2575
followed by the final number of eligible patients and the total number of
an be seen in the Additional file 2.
Table 3 Results of the query execution using the EHR4CR PF system at AP-HP
Study EFPIA partner C1 C2 C3 C4 C5 C6 Eligible patients Patients per clinic
NCT00439725 Bayer 4108 787 313 205 4116
NCT00638690 Janssen 8594 695 356 35 212 −24* 5 8626
NCT00626548 AstraZeneca 8594 6745 695 695 8626
Columns C1 to C6 show the number of eligible patients for every single criterion, followed by the final number of eligible patients and the total number of
patients who visited the respective clinics in the year 2012.
*Exclusion criterion.
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thirteen cases (two from AP-HP and one from UKM),
whereas in six other cases, the more accurate counts
were the clinician estimations (five from UKM and one
from AP-HP). In two out of the thirteen cases both of
the processes provided counts within the confidence
interval of the “alloyed” gold standard.
Efficiency
The creation, execution and visualization of a query
using the EHR4CR PF system required between five and
25 minutes depending on the complexity of the query
(five minutes for a query with three criteria and 25 with
26 criteria).
The time required to receive the response from the
PIs varied depending on whether the questionnaire was
sent by the EFPIA representative or directly by the site.
In the former case, the response to the questionnaire
was received in seven calendar days, whereas in the lat-
ter it required between 30 and 90 days.
100 patients records test
The chart review performed by a medical expert showed
that 34 out of 100 randomly selected patients would beTable 4 Results of the chart review at UKM
Study EFPIA partner Results chart
review
Gold Standard-Mean
[LB – HB]
Patients
per clinic
NCT00439725 Bayer 3 42 [14 – 120] 1411
NCT00345839 Amgen 1 74 [13 – 406] 7439
NCT00627640 Merck 2 112 [30 – 393] 5607
NCT00894387 Novartis 4 75 [29 – 186] 1885
NCT00638690 Janssen 2 31 [8 – 108] 1540
NCT00626548
AstraZeneca
14 216 [131 – 341] 1540
NCT00715624 Sanofi 0 0 [0 – 96] 2575
NCT01018173 Roche 34 876 [655 – 1126] 2575
NCT01468987 Eli Lilly 10 257 [142 – 449] 2575
NCT00490139 GSK 4 22 [8 – 54] 546
Matching patients for the 100 records manually checked at UKM, total number
of patients per clinic and mean result of the extrapolation using the ci-Wilson
score with a 95% of confidence together with the lower and upper bounds
and the total number of patients who visited the clinic in the year 2012.eligible for the NCT01018173-Roche study at UKM. The
EHR4CR PF system identified eleven out of the 34 eli-
gible patients (without false-positives). We found out
that the medical expert had access to data from several
clinics at the hospital rather than only from the clinic
evaluated. To close this gap, all data available related to
the given patient set derived from the seven clinics we
had approvals from were loaded in the CDW for the
given patient set. The EHR4CR PF system was then uti-
lized again, which led to an increase of eligible patients
found by the system: 23 out of 34 eligible patients with
none false-positives. The remaining eleven mismatches
were evaluated individually by accessing the respective
patient records and discovering that the data related to
the criteria which caused the EHR4CR PF system mis-
matches were solely written as free text in some of the
clinical letters.
Discussion
Answers to study questions
This evaluation shows a relatively low accuracy in the
counts obtained following both manual and EHR4CR PF
supported processes at the two evaluated sites. The ac-
curacy of the EHR4CR PF system depends on the quality
of the data in the CDWs. A high level of quality that
produces accurate results is only reached if the data in
the EHR source is well documented and structured. If
this is not the case, the EC become too restrictive and
the EHR4CR PF system returns no matching patients.
This can be stated after reviewing Tables 6 and 7: While
the results in a less structured EHR as the one in UKM
show an accuracy higher than PI responses in one out ofTable 5 Results of the chart review at AP-HP
Study EFPIA partner Results chart
review
Gold Standard-Mean
[LB – HB]
Patients
per clinic
NCT00439725 Bayer 12 494 [288 – 816] 4116
NCT00638690 Janssen 1 86 [15 – 470] 8626
NCT00626548
AstraZeneca
12 1035 [603 – 1709] 8626
Matching patients for the 100 records manually checked at AP-HP, total number of
patients per clinic and mean result of the extrapolation using the ci-Wilson score
with a 95% of confidence together with the lower and upper bounds and the total
number of patients who visited the clinic in the year 2012.
Table 6 Overall results at UKM
Study EFPIA partner Results current process Results EHR4CR PF system Gold Standard-Mean [LB – HB] Patients per clinic
NCT00439725 Bayer 30 0 42 [14 – 120] 1411
NCT00345839 Amgen 200 0 74 [13 – 406] 7439
NCT00627640 Merck 300 0 112 [30 – 393] 5607
NCT00894387 Novartis 25 0 75 [29 – 186] 1885
NCT00638690 Janssen 50 0 31 [8 – 108] 1540
NCT00626548 AstraZeneca 200 174 216 [131 – 341] 1540
NCT00715624 Sanofi 12 18 0 [0 – 96] 2575
NCT01018173 Roche 340 566 876 [655 – 1126] 2575
NCT01468987 Eli Lilly 110 8 257 [142 – 449] 2575
NCT00490139 GSK 10 0 22 [8 – 54] 546
Overview of the results obtained by current and EHR4CR supported processes for each of the trials evaluated at UKM and comparison with the gold standard.
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within the bounds of the gold standard), the results from
APHP show a better accuracy of the EHR4CR PF system
in two out of three cases. The importance of structure
data is present in other studies [20] and clinicians should
be made aware of it.
The process of obtaining patient counts using the
EHR4CR PF system has proven not only to be faster
than the current manual process (saving approximately
seven calendar days per query) but also simpler and
therefore less resource consuming. Once the EHR4CR
PF system is set up, a user can query several sites with-
out involving personnel from the clinics in the process.
Relevant differences have been discovered between the
results obtained in the two different sites evaluated. One
of them is based on an EHR with more structured data
and the counts obtained using the EHR4CR PF system
were much closer to the “alloyed” gold standard than
the second site. The accuracy of the EHR4CR system
varies depending on the kind and number of EC, becom-
ing less accurate with a higher number or more exclu-
sive EC. With the manual review of clinical records, the
existence of matching patients for the trials in the EHRs
was proved.
We have identified several reasons for the EHR4CR PF
mismatches:
The use of free text as unstructured data was the prin-
cipal reason for mismatches between the EHR4CR PF
system and the “alloyed” gold standard. As an example,Table 7 Overall results at AP-HP
Study EFPIA partner Results current process Results EHR4CR
NCT00439725 Bayer 20 205
NCT00638690 Janssen 25 5
NCT00626548 AstraZeneca 250 695
Overview of the results obtained by current and EHR4CR supported processes for emedication is often stored as free text. It was also
discovered that the diagnosis, assumed to be always
documented in a structured way, is often only avail-
able in the EHRs as free text. For the reviewed cases,
this happened only when the diagnosis was not the
primary diagnosis.
Some of the EC evaluated such as the FISH test or the
biPTH lab value are just not part of any tests followed in
the evaluated sites. Instead, there are similar test with
different names. The solution would be to adapt the EC
to the countries or sites evaluated.
The EHR4CR consortium uses several controlled ter-
minologies and classifications such as SNOMED-CT and
ICD-10, but the consortium has also created its own ter-
minology. This terminology responds to the need of the
study sponsors to query for EC not available or not
found in the existing terminologies and classifications
(e.g.: “Transplant list” if the patient is in a transplant
list). The EHR4CR terminology has some limitations
though: it is not controlled and quite complicated to
map to the existing standards. The authors recommend
that the elements belonging to this terminology should
be either replaced by similar elements in the existing
controlled terminologies and classifications or included
as part of the EHRs in order to facilitate the ETL.
Another reason for the mismatches is that some of
the data are just not electronically documented and/or
could not be found, as for example data existent only
on paper. This concurs with Kopcke’s findings [21],PF system Gold Standard-Mean [LB – HB] Patients per clinic
494 [288 – 816] 4116
86 [15 – 470] 8626
1035 [603 – 1709] 8626
ach of the trials evaluated at AP-HP and comparison with the gold standard.
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support clinical trials in EHRs.
In some cases, the data available in the EHRs were
sufficient to deduce some of the criteria and therefore
the eligibility of the patient. For example, the Hoehn and
Yahr classification is not documented as such, but a score
could be deduced from the physician notes. Currently
this is only possible with a chart review and not computed
by the current ETL.
These reasons are similar to the ones found by Hersh
[22], who also provides possible solutions to them. Sev-
eral studies have assessed the quality of data in EHRs
and provide guidelines on how to improve it [23-25]. A
site willing to become an EHR4CR data provider, should
use these data quality guidelines in order to become a
useful member of the project. Besides, the data elements
in the EHR4CR terminology services need to be compli-
ant with the data existing at the sites and the ETL pro-
cesses improved in order to deal with the currently
ignored data.
The responses from the physicians to the question:
“What process do you usually follow to answer a poten-
tial sponsor’s feasibility/site questionnaire?” showed that
the process followed in order to answer these question-
naires is based on the clinicians own experience and
they normally do not check historical records for their
responses. The EHR4CR PF system on the other hand,
provides objective data based on historical data.
One of the biggest advantages of the EHR4CR PF
system is its flexibility. In this context, flexibility can be
defined as the ability to easily modify the EC and re-run
queries using the platform. In the current process this
would require the creation of a new questionnaire and
re-contacting the clinicians involved in order to get the
number of matching patients for the modified criteria.
This study showed that it can take approximately seven
days to obtain responses from clinicians whereas the
EHR4CR system only needs a few minutes. Thus we can
state that for every phase of modifications of criteria
using the EHR4CR can save up to seven calendar days.
Strengths and weaknesses of the study
The evaluation at two of the EHR4CR project sites included
900 manually checked patient records, 13 questionnaires
answered by different clinicians and nine different EHR4CR
databases with more than 30 thousand patients from
seven different clinics. The participation of two sites
from two different countries led to important findings
and differences between them.
The simplification process of the study criteria might
have caused mistakes in the final feasibility EC utilized.
The root cause for this problem is that current EC are
available as non-computable free text. In principle, this
should not alter the evaluation as the same final EC wereevaluated following the three methods (the simulation of
the current process, the process using the EHR4CR
PF system and the chart review). However, in the au-
thors’ opinion, the EC used for some of the studies
(e.g.: GSK – NCT00894387 with 26 EC before and
after the simplification) could be closer to the final
study criteria rather than just feasibility criteria, as
they are normally simpler and less restrictive.
The feasibility questionnaires were only sent by EFPIA
representatives in three of the cases, in the other ten
cases the site had to approach the clinicians. The lack of
commercial interest for this task might result in a delay
on the response. This lack of interest is evident when
the physicians where approached by the sites, resulting
in some of the cases in a delay of more than three months.
As this value is not realistic, the only measurement
considered valid in a real-world setting was the one
obtained when the site was approached by the EFPIA
partner (seven calendar days).
Due to the shifted dates of the data in the CDWs, tem-
poral constraints of the EHR4CR queries were adapted
in order to obtain all possible true positive eligible pa-
tients, resulting in an eventual increase of false positives.
However, the manual check of a representative set of
patients for the study NCT01018173 suggests that
EHR4CR queries tend to discover too few true positives,
but no false positives.
Results in relation to other studies
Despite the rising awareness of the importance of health
information system evaluations, the authors could not
find a similar evaluation to this one in the reviewed lit-
erature. There are several patient cohort systems being
developed across the world. Some of the most promin-
ent ones, such as the Shared Health Research Informa-
tion Network (SHRINE) [26], the Feasibility Assessment
and Recruitment System for Improving Trial Efficiency
(FARSITE) [27] or the Electronic Primary Care Research
Network (ePCRN) [28], also include the possibility to
formulate complex queries and find eligible patients for
a trial. These systems have in common that they operate
with a single EHR data source. The EHR4CR PF system
operates with several different data sources (MySQL,
SQL Server, Oracle and PostgreSQL) and technologies.
Moreover, these systems offer a quite limited capability
in regard to their temporal reasoning when this is com-
pared to the EHR4CR PF services [15].
Meaning and generalizability of the study
This research has found crucial issues that hamper the
re-use of EHR data for clinical research and proposes
solutions for them. Besides, the study establishes a
method to evaluate the efficacy and the effectiveness of
similar systems. The same methodology or an adapted
Soto-Rey et al. BMC Medical Research Methodology  (2015) 15:44 Page 9 of 10one could be re-used to assess the availability and qual-
ity of EHR data in a specific clinical site and its potential
to become an EHR4CR data provider.
Unanswered and new questions
The improvement of the ETL process must continue in
order to reuse all available information within the EHR
data sources. All of the reasons for the EHR4CR PF sys-
tem mismatches need to be independently treated and
the recommendations and guidelines for data quality
previously cited in this manuscript considered as a solu-
tion for them. One of the most relevant improvements
could be the inclusion of natural language processing
tools in order to extract and transform the data stored
in free text. Once these improvements have been
adopted, a new evaluation should be performed to assess
the EHR4CR’s ability to extract eligible patients. An
alternative to the CI-Wilson score to build the gold
standard in a future evaluation would be the mark and
recapture methodology [29], although methods for diag-
nostic tests can only be applied if the data compared are
binomial, i.e. if the gold standard is available for every
observation. With the complete set of patient records
manually checked and the patient list obtained using the
EHR4CR system, a contingency table could be built and
sensitivity and specificity ratios calculated.
Conclusions
This study has demonstrated the potential improvement
of the study design step of clinical trials with the use of
a patient count cohort system. Such a system is able to
provide patient counts in a short period of time, which
reduces the workload on personnel from both the clinics
and the study sponsors and accelerates the overall study
design process. However, the system depends on the
availability of structured data within the EHR data
sources. When such data are available, objective and
accurate patient counts can be obtained. At the current
stage, EHRs need to be enhanced with better structured
data to be easily re-used for research purposes.
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